Pre-existing IgG antibodies cross-reacting with the Fab region of infliximab predict efficacy and safety of infliximab therapy in inflammatory bowel disease

Alimentary Pharmacology and Therapeutics

Volumn 37, Issue 12, 2013, Pages 1172-1183

  Steenholdt, C ^a   Palarasah, Y ^b   Bendtzen, K ^b   Teisner, A ^c   Brynskov, J ^a   Teisner, B ^b   Nielsen, C H ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^c ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; IMMUNOGLOBULIN G; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE;

ADULT; ANTIBODY BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; CROSS REACTION; DENMARK; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; ENTERITIS; FEMALE; HUMAN; MALE; OBSERVATIONAL STUDY; PREDICTION; PRIORITY JOURNAL; PROTEIN BINDING; REMISSION; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; ULCERATIVE COLITIS;

ADULT; ANTIBODIES, MONOCLONAL; COHORT STUDIES; CROSS REACTIONS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN G; INFLAMMATORY BOWEL DISEASES; MALE; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84878018309     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/apt.12330     Document Type: Article

References (37)

1. Dignass A, Van AG, Lindsay JO, et al,. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohns Colitis 2010; 4: 28-62.
2. Lichtenstein GR, Hanauer SB, Sandborn WJ,. Management of Crohn's disease in adults. Am J Gastroenterol 2009; 104: 465-83.
3. Mowat C, Cole A, Windsor A, et al,. Guidelines for the management of inflammatory bowel disease in adults. Gut 2011; 60: 571-607.
4. D'Haens GR, Panaccione R, Higgins PD, et al,. The London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: When to start, when to stop, which drug to choose, and how to predict response? Am J Gastroenterol 2011; 106: 199-212.
5. European Medicines Agency (EMA). European Public Assessment Report (EPAR) for Remicade. Available at: http://www.ema.europa.eu/. Accessed April 29, 2013.
6. Hanauer SB, Feagan BG, Lichtenstein GR, et al,. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359: 1541-9.
7. Gisbert JP, Panes J,. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol 2009; 104: 760-7.
8. Ford AC, Sandborn WJ, Khan KJ, Hanauer SB, Talley NJ, Moayyedi P,. Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2011; 106: 644-59.
9. Louis E, Mary JY, Vernier-Massouille G, et al,. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology 2012; 142: 63-70.
10. Pavy S, Toonen EJ, Miceli-Richard C, et al,. Tumour necrosis factor alpha -308G->A polymorphism is not associated with response to TNFalpha blockers in Caucasian patients with rheumatoid arthritis: systematic review and meta-analysis. Ann Rheum Dis 2010; 69: 1022-8.
11. Vermeire S, Louis E, Carbonez A, et al,. Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease. Am J Gastroenterol 2002; 97: 2357-63.
12. Parsi MA, Achkar JP, Richardson S, et al,. Predictors of response to infliximab in patients with Crohn's disease. Gastroenterology 2002; 123: 707-13.
13. Lionetti P, Bronzini F, Salvestrini C, et al,. Response to infliximab is related to disease duration in paediatric Crohn's disease. Aliment Pharmacol Ther 2003; 18: 425-31.
14. Kugathasan S, Werlin SL, Martinez A, Rivera MT, Heikenen JB, Binion DG,. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease. Am J Gastroenterol 2000; 95: 3189-94.
15. Jurgens M, Mahachie John JM, Cleynen I, et al,. Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol 2011; 9: 421-7.
16. van der Laken CJ, Voskuyl AE, Roos JC, et al,. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. Ann Rheum Dis 2007; 66: 253-6.
17. Ternant D, Aubourg A, Magdelaine-Beuzelin C, et al,. Infliximab pharmacokinetics in inflammatory bowel disease patients. Ther Drug Monit 2008; 30: 523-9.
18. Xu Z, Seitz K, Fasanmade A, et al,. Population pharmacokinetics of infliximab in patients with ankylosing spondylitis. J Clin Pharmacol 2008; 48: 681-95.
19. Allez M, Karmiris K, Louis E, et al,. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohns Colitis 2010; 4: 355-66.
20. Steenholdt C, Svenson M, Bendtzen K, Thomsen OO, Brynskov J, Ainsworth MA,. Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease. Aliment Pharmacol Ther 2011; 34: 51-8.
21. Baert F, Noman M, Vermeire S, et al,. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348: 601-8.
22. Chaparro M, Guerra I, Muñoz-Linares P, Gisbert JP,. Systematic review: antibodies and anti-TNF-alpha-α levels in inflammatory bowel disease. Aliment Pharmacol Ther 2012; 35: 971-86.
23. Lee LY, Sanderson JD, Irving PM,. Anti-infliximab antibodies in inflammatory bowel disease: prevalence, infusion reactions, immunosuppression and response, a meta-analysis. Eur J Gastroenterol Hepatol 2012; 24: 1078-85.
24. Ordas I, Feagan BG, Sandborn WJ,. Therapeutic drug monitoring of tumor necrosis factor antagonists in inflammatory bowel disease. Clin Gastroenterol Hepatol 2012; 10: 1079-87.
25. Kricka LJ,. Human anti-animal antibody interferences in immunological assays. Clin Chem 1999; 45: 942-56.
26. Andersen DC, Koch C, Jensen CH, Skjodt K, Brandt J, Teisner B,. High prevalence of human anti-bovine IgG antibodies as the major cause of false positive reactions in two-site immunoassays based on monoclonal antibodies. J Immunoassay Immunochem 2004; 25: 17-30.
27. Ben-Horin S, Yavzori M, Katz L, et al,. The immunogenic part of infliximab is the F(ab')2, but measuring antibodies to the intact infliximab molecule is more clinically useful. Gut 2011; 60: 41-8.
28. Afif W, Loftus EV Jr, Faubion WA, et al,. Clinical utility of measuring infliximab and human anti-chimeric antibody concentrations in patients with inflammatory bowel disease. Am J Gastroenterol 2010; 105: 1133-9.
29. Steenholdt C, Bendtzen K, Brynskov J, Thomsen OO, Ainsworth MA,. Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease. Scand J Gastroenterol 2011; 46: 310-8.
30. Steenholdt C, Molazahi A, Ainsworth MA, Brynskov J, Ostergaard TO, Seidelin JB,. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study. Scand J Gastroenterol 2012; 47: 518-27.
31. Rutgeerts P, Sandborn WJ, Feagan BG, et al,. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353: 2462-76.
32. Magdelaine-Beuzelin C, Vermeire S, Goodall M, et al,. IgG1 heavy chain-coding gene polymorphism (G1 m allotypes) and development of antibodies-to-infliximab. Pharmacogenet Genomics 2009; 19: 383-7.
33. Ainsworth MA, Bendtzen K, Brynskov J,. Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease. Am J Gastroenterol 2008; 103: 944-8.
34. Vultaggio A, Matucci A, Nencini F, et al,. Anti-infliximab IgE and non-IgE antibodies and induction of infusion-related severe anaphylactic reactions. Allergy 2010; 65: 657-61.
35. MacDermott RP, Nash GS, Auer IO, et al,. Alterations in serum immunoglobulin G subclasses in patients with ulcerative colitis and Crohn's disease. Gastroenterology 1989; 96: 764-8.
36. El Fassi D, Hegedüs L, Nielsen CH,. Anti-CD20 antibody therapy for B-cell lymphomas. N Engl J Med 2012; 367: 877.
37. Hanauer SB, Wagner CL, Bala M, et al,. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2: 542-53.